secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2022-06-03T23:59:59+00:00
Accession:  0001193125-22-167299
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

TScan promotes Gavin MacBeath to CSO and COO; salary raised to $470k
--------------------------------------------------------------------

- Gavin MacBeath, Ph.D., promoted from CSO to Chief Scientific and Operations Officer effective June 1, 2022.
- Annual base salary increased to $470,000 in connection with promotion.
- Stockholders elected Timothy Barberich and Stephen Biggar as Class I directors for three-year terms.
- Ratification of Deloitte & Touche as independent auditor for FY2022 approved with 11.5M votes for, 425 against.
- All votes at Annual Meeting held June 1, 2022; results filed via 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312522167299/0001193125-22-167299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312522167299/d348966d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-167299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer